@article{TAU10425,
author = {Brittani Barrett-Harlow and Run Wang},
title = {Oral therapy for Peyronie’s disease, does it work?},
journal = {Translational Andrology and Urology},
volume = {5},
number = {3},
year = {2016},
keywords = {},
abstract = {Peyronie’s disease (PD) is a localized, wound-healing, connective tissue disorder of the penis characterized by scarring of the tunica albuginea. This fibrous inelastic scar leads to penile pain, penile deformity and erectile dysfunction (ED), and a difficulty performing coitus. Over the past several decades, a myriad of oral agents for the treatment of PD have been studied and suggested. While the gold standard of care remains surgical therapy, many physicians continue to prescribe oral and intralesional injections for treatment during the acute phase of the disease. This article seeks to summarize the different oral therapy agents for PD and the research associated with each medication. While the American Urological Association has not recommended most of the mentioned medications for the treatment of PD, two newer therapies have shown success and have the potential of becoming baseline treatments for the acute phase of PD.},
issn = {2223-4691}, url = {https://tau.amegroups.org/article/view/10425}
}